Immunogenicity and Immune Cell Assays Patents: Who Leads, Where the Gaps Are
Filing concentrated at the top, long tail beneath. The five leading assignees hold 20.9% of all 4,723 records in scope; the leading ten hold 30.6%, with 100 ranked companies in total. Filings peaked at 509 in 2017. Using only the years that can be treated as complete, 2021 filings (361) fell to 266 by 2024 — a -26% change over that three-year span. Years after 2024 should not be read as a continued drop; they are still being backfilled by publication lag.
- 1BRISTOL MYERS SQUIBB CO5.3%
- 2MODERNATX INC5.0%
- 3CIRCASSIA LIMITED4.5%
- 4MERCK PATENT GMBH3.7%
- 5MEDIMMUNE LTD2.5%
See the full immunogenicity and immune cell assays analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions about this landscape
What counts as an immunogenicity or immune cell assay patent in this dataset?
This dataset covers records that combine immunogenicity-testing language — immunogenicity assay, cytokine release assay, or anti-drug antibody — with terms describing how the assay is built or controlled, such as donor panel size, assay format choice, background variability, positive control selection, antigen presentation, or T cell proliferation. It spans filings published between 2015 and the 2026 cut-off, drawn from 4,723 records. It is not limited to any single therapeutic class, though the composition data shows most records also carry antibody or peptide-based therapeutic claims.
Why did immunogenicity assay filings peak in 2017 and decline afterward?
The 2017 peak of 509 filings reflects a period of heavy activity around checkpoint-antibody and bispecific-construct patenting, much of which required paired immunogenicity and ADA-testing claims. The apparent decline in the most recent one to two years is partly real and partly an artefact of publication lag, since patent applications typically publish around 18 months after filing. The only comparison that can be read reliably is the complete-year one: 2021's 361 filings falling to 266 by 2024, a -26% change, which does indicate genuine cooling rather than a lag effect.
Which companies lead in immunogenicity and immune cell assay patents?
The ranked leaders in this dataset span 100 companies, with the top-ranked assignee holding 251 records and the fifth-ranked holding 117. Together the five leading assignees account for 20.9% of the 4,723 records in scope, and the leading ten account for 30.6% — meaning filing is concentrated at the top but with a long tail of single- or few-filing entrants beyond the leaders. Recent-year momentum data shows some leaders still actively filing while others in the same ranked group have gone quiet, which matters more for freedom-to-operate risk than raw historical volume.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Immunogenicity and Immune Cell Assays covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.